Cargando…
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS:...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283619/ https://www.ncbi.nlm.nih.gov/pubmed/35653062 http://dx.doi.org/10.1007/s41669-022-00335-5 |
_version_ | 1784747364579278848 |
---|---|
author | Reaney, Matthew Allen, Veleka Sehnert, Amy J. Fang, Liang Hagège, Albert A. Naidu, Srihari S. Olivotto, Iacopo |
author_facet | Reaney, Matthew Allen, Veleka Sehnert, Amy J. Fang, Liang Hagège, Albert A. Naidu, Srihari S. Olivotto, Iacopo |
author_sort | Reaney, Matthew |
collection | PubMed |
description | BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS: Cognitive debriefing interviews and a card-sorting task were conducted in 33 patients with HCM to support development of the HCMSQv1.0, showing the scale to be interpretable and relevant to patients’ experiences. Baseline blinded data from two trials (EXPLORER-HCM and MAVERICK-HCM) were pooled (N = 299) to develop the scoring algorithm of HCMSQv1.0. Measurement properties were examined, followed by a meaningful-change analysis to interpret scores. Rasch modeling, mixed-model repeated measures, exploratory factor analysis, confirmatory factor analysis, and missing-data simulation analysis informed the number of domains and the items in each domain. RESULTS: The scoring algorithm for HCMSQv1.0 consists of four domains: shortness of breath, tiredness, cardiovascular symptoms, and syncope; plus a total score, with higher scores indicating more severe symptoms. Item characteristics, internal consistency, test–retest reliability, construct validity, and responsiveness were acceptable. A clinically meaningful responder definition of 1–2 points on the HCMSQv1.0 score for shortness of breath and total score, and approximately 1 point on the tiredness and cardiovascular symptom scores, was calculated based on distribution- and anchor-based methods. CONCLUSION: Our findings support the HCMSQv1.0 as a fit-for-purpose PRO instrument for assessing treatment benefit in patients with HCM. Studies in larger patient populations are ongoing to confirm responder definition and scoring approaches encompassing key HCM symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00335-5. |
format | Online Article Text |
id | pubmed-9283619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92836192022-07-16 Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument Reaney, Matthew Allen, Veleka Sehnert, Amy J. Fang, Liang Hagège, Albert A. Naidu, Srihari S. Olivotto, Iacopo Pharmacoecon Open Original Research Article BACKGROUND: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). OBJECTIVE: We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version 1.0 (HCMSQv1.0). METHODS: Cognitive debriefing interviews and a card-sorting task were conducted in 33 patients with HCM to support development of the HCMSQv1.0, showing the scale to be interpretable and relevant to patients’ experiences. Baseline blinded data from two trials (EXPLORER-HCM and MAVERICK-HCM) were pooled (N = 299) to develop the scoring algorithm of HCMSQv1.0. Measurement properties were examined, followed by a meaningful-change analysis to interpret scores. Rasch modeling, mixed-model repeated measures, exploratory factor analysis, confirmatory factor analysis, and missing-data simulation analysis informed the number of domains and the items in each domain. RESULTS: The scoring algorithm for HCMSQv1.0 consists of four domains: shortness of breath, tiredness, cardiovascular symptoms, and syncope; plus a total score, with higher scores indicating more severe symptoms. Item characteristics, internal consistency, test–retest reliability, construct validity, and responsiveness were acceptable. A clinically meaningful responder definition of 1–2 points on the HCMSQv1.0 score for shortness of breath and total score, and approximately 1 point on the tiredness and cardiovascular symptom scores, was calculated based on distribution- and anchor-based methods. CONCLUSION: Our findings support the HCMSQv1.0 as a fit-for-purpose PRO instrument for assessing treatment benefit in patients with HCM. Studies in larger patient populations are ongoing to confirm responder definition and scoring approaches encompassing key HCM symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00335-5. Springer International Publishing 2022-06-02 /pmc/articles/PMC9283619/ /pubmed/35653062 http://dx.doi.org/10.1007/s41669-022-00335-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Reaney, Matthew Allen, Veleka Sehnert, Amy J. Fang, Liang Hagège, Albert A. Naidu, Srihari S. Olivotto, Iacopo Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title | Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title_full | Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title_fullStr | Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title_full_unstemmed | Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title_short | Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument |
title_sort | development of the hypertrophic cardiomyopathy symptom questionnaire (hcmsq): a new patient-reported outcome (pro) instrument |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283619/ https://www.ncbi.nlm.nih.gov/pubmed/35653062 http://dx.doi.org/10.1007/s41669-022-00335-5 |
work_keys_str_mv | AT reaneymatthew developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT allenveleka developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT sehnertamyj developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT fangliang developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT hagegealberta developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT naidusriharis developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument AT olivottoiacopo developmentofthehypertrophiccardiomyopathysymptomquestionnairehcmsqanewpatientreportedoutcomeproinstrument |